Skip to main content

Table 2 TDI focal score and SGRQ-C total score after 4 weeks (full analysis set)

From: A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD

Ensifentrine doseTDI focal scoreSGRQ-C total score
Mean (SD)Treatment–placebo difference (95% confidence interval); p valueMean (SD)Treatment–placebo difference (95% confidence interval); p value
6 mg (N = 80)1.39 (2.179)1.11 (0.16 to 2.06); 0.02241.5 (15.20)−2.67 (− 6.26 to 0.91); 0.143
3 mg (N = 82)1.55 (3.436)1.19 (0.25 to 2.14); 0.01440.1 (15.93)−2.29 (−5.96 to 1.37); 0.220
1.5 mg (N = 81)1.92 (3.221)1.64 (0.69 to 2.59); 0.00141.4 (16.24)−2.85 (−6.46 to 0.76); 0.121
0.75 mg (N = 81)1.49 (2.810)1.29 (0.32 to 2.25); 0.00945.1 (14.95)−2.22 (−5.87 to 1.42); 0.231
Placebo (N = 79)0.37 (3.220) 43.5 (16.99) 
  1. Abbreviations: TDI, Transition Dyspnoea Index; SGRQ-C, St George’s Respiratory Questionnaire – Chronic Obstructive Pulmonary Disease Specific